Certara's Slumping Returns on Capital Raise Investor Concerns Amid Growth Push
While the biosimulation leader reports rising revenues and capital investment, its key profitability metric—Return on Capital Employed—has declined to 2.2%, significantly trailing the healthcare services sector. Analysts question whether current growth investments will translate into future shareholder value.